Join our daily newsletter At The Bell to receive exclusive market insights
In a matter of weeks, Tryptamine Therapeutics (ASX:TYP) will become the world’s first company to conduct a study using IV-injected ‘magic mushroom’ psychedelic psilocin in a bid to manage binge eating behaviours in a patient now enrolled and undergoing baseline data assessments.
For years many have touted the benefits of such chemicals when it comes to enhancing psychological therapies, particularly addictive behaviours.
There’s no shortage of formal and informal scientific literature that hypothesises psychedelics can act as a ‘circuit breaker’ (alongside guided therapy) which could assist alcoholics, and binge eaters, in ramping down impulsive decisions.
Soon, we’ll be in a world where at least one study will lend hard credence or otherwise to that hypothesis. While the company is currently dealing with collecting baseline data for its first patient, others are in the wings. The company reports a strict application process.
In other words: weeding out people who just want to get shot up with a psychedelic. (Fun fact, that’s how famous author Aldous Huxley decided to go out when he had his wife inject him with LSD on his deathbed.)
The total trial size will involve 12 patients, all of whom will be dosed twice, two weeks apart. Secondary data will be harvested when it comes to the efficacy of TRP-8803 (the extracted psychedelic compound Tryptamine will be using and, all cards in order, commercialising in the future) which is also patented.
To try and underscore the actual efficacy of stopping patients from binge eating, the company will weigh patients following the conclusion of the trial (assuming a change in eating habits will occur) as far out as 12 weeks; depression, anxiety and frequency of binge eating episodes will also be measured.
TYP last traded at 3.9cps.
Join the discussion: See what HotCopper users are saying about TYP and be part of the conversations that move the markets.
